

SEKK s.r.o., Divize EHK, Arnošta z Pardubic 2605, 530 02 Pardubice, Česká republika
Poskytovatel zkoušení způsobilosti č. 7004 akreditovaný ČIA dle ČSN EN ISO/IEC 17043.
Podrobnosti o předmětu a rozsahu akreditace naleznete na: <https://www.sekk.cz>

OSVĚDČENÍ O ÚČASTI

Cyklus EHK: AKS2/23 - Analyty krevního séra

Stop termín (uzávěrka cyklu EHK): 7.4.2023

Oborná garance: Česká společnost klinické biochemie ČLS JEP (ČSKB)

Účastník: Krajská nemocnice T. Bati, a. s., Oddělení klinické biochemie a farmakologie
Havlíčkovo nábřeží 600, 762 75 Zlín, Česká republika IČO: 27661989
Prim. MUDr. Tomáš Šálek, Ph.D., EuSpLM

Potvrzujeme, že výše uvedený účastník se zúčastnil cyklu externího hodnocení kvality pro následující zkoušky:

Zkouška

ID měřicího systému

α-amyláza

Architect ci16200-II

Albumin

Architect ci16200-II

ALP

Architect ci16200-II

ALT

Architect ci16200-II

AST

Architect ci16200-II

Bilirubin celkový

Architect ci16200-II

Celková bílkovina

Architect ci16200-II

Draselný kation

Architect ci16200-II

Fosfáty anorganické

Architect ci16200-II

GGT

Architect ci16200-II

Glukóza

Architect ci16200-II

Chloridový anion

Architect ci16200-II

Cholesterol

Architect ci16200-II

Cholinesteráza

Architect ci16200-II

Kreatinin

Architect ci16200-II

Kyselina močová

Architect ci16200-II

LD

Architect ci16200-II

Zkouška

ID měřicího systému

Lipáza

Architect ci16200-II

Močovina

Architect ci16200-II

Sodný kation

Architect ci16200-II

Triacylglyceroly

Architect ci16200-II

Vápník celkový

Architect ci16200-II

Toto osvědčení platí do: 7.4.2024

Ing. Marek Budina
ředitel společnosti SEKK

doc. Ing. Drahomíra Springer, Ph.D.
předsedkyně ČSKB

SEKK s.r.o., EQA division, Arnošta z Pardubic 2605, 530 02 Pardubice, Czech Republic
 Provider of proficiency testing schemes no. 7004 accredited by CAI according to ISO/IEC 17043.
 Details concerning the subject and scope of the accreditation should be found on: <https://www.sekk.cz>

CONFIRMATION OF ATTENDANCE

EQA round: AKS2/23 - Basic Clinical Chemistry - Serum

Deadline (EQA round closed): 7.4.2023

Professional supervision: Czech Society of Clinical Biochemistry (CSCB)

Participant: Krajská nemocnice T. Bati, a. s., Oddělení klinické biochemie a farmakologie
 Havlíčkovo nábřeží 600, 762 75 Zlín, Czech Republic CID: 27661989
 Prim. MUDr. Tomáš Šálek, Ph.D., EuSpLM

This is to confirm that the above mentioned participant participated in this EQA round for the following tests:


Test	ID of measuring system
α-amylase	Architect ci16200-II
Albumin	Architect ci16200-II
ALP	Architect ci16200-II
ALT	Architect ci16200-II
AST	Architect ci16200-II
Bilirubin total	Architect ci16200-II
Total protein	Architect ci16200-II
Potassium	Architect ci16200-II
Inorganic phosphate	Architect ci16200-II
gamma-GT	Architect ci16200-II
Glucose	Architect ci16200-II
Chloride	Architect ci16200-II
Cholesterol	Architect ci16200-II
Cholinesterase	Architect ci16200-II
Creatinine	Architect ci16200-II
Uric acid	Architect ci16200-II
LD	Architect ci16200-II

Test	ID of measuring system
Lipase	Architect ci16200-II
Urea	Architect ci16200-II
Sodium	Architect ci16200-II
Triacylglycerols	Architect ci16200-II
Calcium	Architect ci16200-II

This confirmation expires on: 7.4.2024



Marek Budina, MSc
 director of SEKK



Assoc. Prof. Drahomíra Springer, PhD
 chairwoman of the CSCB